Table 5 Response and MRD-negativity rates (ITT population)a.

From: Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA

 

Non-frailb

Frail

 

Fit (19.8%c; n = 146/737)

Intermediate (33.9%c; n = 250/737)

Total–non-frailb (53.7%c; n = 396/737)

Frail (46.3%c; n = 341/737)

 

D-Rd (18.5%d; n = 68/368)

Rd (21.1%e; n = 78/369)

P value

D-Rd (34.8%d; n = 128/368)

Rd (33.1%e; n = 122/369)

P value

D-Rd (53.3%d; n = 196/368)

Rd (54.2%e; n = 200/369)

P value

D-Rd (46.7%d; n = 172/368)

Rd (45.8%e; n = 169/369)

P value

ORR

68 (100.0)

65 (83.3)

0.0004

124 (96.9)

104 (85.2)

0.0012

192 (98.0)

169 (84.5)

<0.0001

150 (87.2)

132 (78.1)

0.0265

 ≥CR, n (%)

38 (55.9)

17 (21.8)

<0.0001

69 (53.9)

31 (25.4)

<0.0001

107 (54.6)

48 (24.0)

<0.0001

75 (43.6)

52 (30.8)

0.0144

  sCR

27 (39.7)

13 (16.7)

0.0019

44 (34.4)

9 (7.4)

<0.0001

71 (36.2)

22 (11.0)

<0.0001

49 (28.5)

29 (17.2)

0.0129

  CR

11 (16.2)

4 (5.1)

 

  25 (19.5)

22 (18.0)

 

  36 (18.4)

26 (13.0)

 

26 (15.1)

23 (13.6)

 

 ≥VGPR, n (%)

59 (86.8)

42 (53.8)

<0.0001

108 (84.4)

70 (57.4)

<0.0001

167 (85.2)

112 (56.0)

<0.0001

128 (74.4)

91 (53.8)

<0.0001

  VGPR

21 (30.9)

25 (32.1)

 

39 (30.5)

39 (32.0)

 

  60 (30.6)

64 (32.0)

 

53 (30.8)

39 (23.1)

 

 PR

9 (13.2)

23 (29.5)

 

  16 (12.5)

34 (27.9)

 

  25 (12.8)

57 (28.5)

 

22 (12.8)

41 (24.3)

 

 SD

0

11 (14.1)

 

3 (2.3)

18 (14.8)

 

  3 (1.5)

29 (14.5)

 

8 (4.7)

26 (15.4)

 

 PD

0

0

 

0

0

 

  0

0

 

  1 (0.6)

0

 

 NE

0

2 (2.6)

 

  1 (0.8)

0

 

  1 (0.5)

2 (1.0)

 

  13 (7.6)

11 (6.5)

 

MRD negative (10–5), n (%)

23 (33.8)

6 (7.7)

<0.0001

42 (32.8)

11 (9.0)

<0.0001

65 (33.2)

17 (8.5)

<0.0001

41 (23.8)

17 (10.1)

0.0008

  1. MRD minimal residual disease, ITT intent-to-treat, D-Rd daratumumab plus lenalidomide/dexamethasone, Rd lenalidomide/dexamethasone, ORR overall response rate, ≥CR complete response or better, sCR stringent complete response, CR complete response, ≥VGPR very good partial response or better, VGPR very good partial response, PR partial response, SD stable disease, PD progressive disease, NE not evaluable.
  2. aPercentages in the table were calculated using the number of patients in each treatment cohort per frailty subgroup of the ITT population (fit: D-Rd, n = 68; Rd, n = 78; intermediate: D-Rd, n = 128; Rd, n = 122; total–non-frail: D-Rd, n = 196; Rd, n = 200; frail: D-Rd, n = 172; Rd, n = 169) as the denominator, unless otherwise indicated.
  3. bNon-frail subgroup consists of fit and intermediate patients.
  4. cPercentage was calculated using the number of patients in the ITT population as the denominator.
  5. dPercentage was calculated using the number of patients in the D-Rd cohort of the ITT population as the denominator.
  6. ePercentage was calculated using the number of patients in the Rd cohort of the ITT population as the denominator.
Back to article page